[SCHEDULE 13G] Silexion Therapeutics Corp SEC Filing

Rhea-AI Filing Summary

Orca Capital AG disclosed ownership of 131,250 ordinary shares of Silexion Therapeutics Corp (CUSIP G1281K130), representing 6.2% of the outstanding class based on 2,123,892 shares after the issuer's registered offering. Orca reports sole voting and dispositive power over these shares. The filing notes Orca holds warrants for 262,500 additional shares but cannot exercise them to the extent doing so would increase its stake above a 4.99% blocker under the warrant terms. The statement affirms the position was not acquired to change or influence control of the issuer.

Insights

Financial Analyst

TL;DR: Orca Capital holds a disclosed 6.2% stake with full voting control of those shares; warrant exercise is contractually limited to 4.99%.

Orca's reported 6.2% stake is material under SEC rules and signals a meaningful minority position that may attract investor attention. The filing clarifies sole voting and dispositive power for 131,250 shares, which gives Orca unilateral control over voting those shares. The presence of warrants for 262,500 shares is notable, but the explicit 4.99% blocker prevents immediate dilution above the threshold and limits potential near-term escalation of ownership through warrant exercise. This disclosure is routine for an investor crossing the 5% threshold and does not by itself indicate an intent to change control.

Corporate Governance Expert

TL;DR: Filing is a standard Section 13G disclosure showing a passive-claimant position with contractual limits on additional share acquisition.

The certification states the securities were not acquired to influence control, consistent with a Schedule 13G filing rather than a Schedule 13D. For governance, sole voting power over a >5% block can still create influence despite the passive filing status, particularly on shareholder votes. However, the 4.99% blocker on warrant exercise constrains Orca's ability to increase ownership via those instruments, reducing immediate governance escalation risk. Investors and the board should note the holder's capacity to vote a meaningful minority stake but also the contractual cap on warrant-driven dilution.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Silexion Therapeutics Corp

(Name of Issuer)

Ordinary Shares, par value $0.0135 per share

(Title of Class of Securities)

G1281K130

(CUSIP Number)

09/11/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. G1281K130

1

Names of Reporting Persons

Orca Capital AG

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

GERMANY

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 131,250.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 131,250.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

131,250.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.2 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: All ownership percentages set forth in this Schedule 13G are calculated based upon an aggregate of 2,123,892 Ordinary Shares outstanding immediately after giving effect to the completion of the Issuer's registered offering and excludes 262,500 Ordinary Shares issuable upon the exercise of warrants held by the Reporting Person, subject to the 4.99% blocker (defined below). Pursuant to the terms of the warrants, as described in the Issuer's Prospectus filed pursuant to Rule 424(b)(4) with the Securities and Exchange Commission on September 12, 2025, the Reporting Person cannot exercise any of the warrants to the extent the Reporting Person would beneficially own, after any such exercise, more than 4.99% of the Issuer's outstanding Ordinary Shares (the "4.99% Blocker").

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Silexion Therapeutics Corp
(b)	Address of issuer's principal executive offices: 12 Abba Hillel Road, Ramat Gan, Israel 5250606
Item 2.
(a)	Name of person filing: Orca Capital AG
(b)	Address or principal business office or, if none, residence: Sperlring 2 85276 Hettenshausen Deutschland
(c)	Citizenship: Germany
(d)	Title of class of securities: Ordinary Shares, par value $0.0135 per share
(e)	CUSIP No.: G1281K130
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 131,250
(b)	Percent of class: 6.2%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 131,250
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 131,250
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Orca Capital AG

Signature:	/s/ Thomas Konig
Name/Title:	Thomas Konig/Director
Date:	09/15/2025